Biogen Reports 15% Earnings Growth, 9% Revenue Gains - Adviser Investments

Biogen Reports 15% Earnings Growth, 9% Revenue Gains

Ryan Christensen, account executive at Adviser Investments, has the market analysis for Tuesday, July 24. The Dow Jones Industrial Average and S&P 500 gained 0.8% and 0.5%, respectively, while the NASDAQ Composite declined fractionally. For earnings, we saw Biogen (ticker: BIIB) top expectations with 15% earnings per share growth and 9% revenue advances. BIIB closed the day up nearly 6%. Investors continue to react favorably to Biogen’s stock as the company is scheduled to present clinical trials on its experimental BAN2401 therapy at this week’s Alzheimer’s Association International Conference.

Recent Videos

View All Videos

Third-Quarter Outlook: Slow Growth Is Not No Growth—Earnings Still Rising

Amazon Cloud Business Revenue up 49%

Facebook Drops 10%; Amazon Gains 2%

Dan Wiener Talks Fund Managers and Tax Inefficiencies

85 Wells Avenue, Suite 109
Newton, MA, 02459

info@adviserinvestments.com 1.800.492.6868

Adviser Investments' logo is a registered trademark of Adviser Investments, LLC.